Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial.
Identifieur interne : 000D50 ( PubMed/Corpus ); précédent : 000D49; suivant : 000D51Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial.
Auteurs : Amanda H. Yao ; Cecilia L. Moore ; Poh Lian Lim ; Jean-Michel Molina ; Juan Sierra Madero ; Stephen Kerr ; Paddy Wg Mallon ; Sean Emery ; David A. Cooper ; Mark A. BoydSource :
- Antiviral therapy [ 2040-2058 ] ; 2017.
Abstract
To investigate metabolic changes associated with second-line antiretroviral therapy (ART) following virological failure of first-line ART.
DOI: 10.3851/IMP3171
PubMed: 28447585
Links to Exploration step
pubmed:28447585Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial.</title><author><name sortKey="Yao, Amanda H" sort="Yao, Amanda H" uniqKey="Yao A" first="Amanda H" last="Yao">Amanda H. Yao</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Moore, Cecilia L" sort="Moore, Cecilia L" uniqKey="Moore C" first="Cecilia L" last="Moore">Cecilia L. Moore</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Lim, Poh Lian" sort="Lim, Poh Lian" uniqKey="Lim P" first="Poh Lian" last="Lim">Poh Lian Lim</name><affiliation><nlm:affiliation>Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore.</nlm:affiliation></affiliation></author><author><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name><affiliation><nlm:affiliation>Department of Infectious Diseases, Hôpital Saint-Louis, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Madero, Juan Sierra" sort="Madero, Juan Sierra" uniqKey="Madero J" first="Juan Sierra" last="Madero">Juan Sierra Madero</name><affiliation><nlm:affiliation>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.</nlm:affiliation></affiliation></author><author><name sortKey="Kerr, Stephen" sort="Kerr, Stephen" uniqKey="Kerr S" first="Stephen" last="Kerr">Stephen Kerr</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Mallon, Paddy Wg" sort="Mallon, Paddy Wg" uniqKey="Mallon P" first="Paddy Wg" last="Mallon">Paddy Wg Mallon</name><affiliation><nlm:affiliation>School of Medicine, University College Dublin, Dublin, Ireland.</nlm:affiliation></affiliation></author><author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW, Sydney, Australia.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28447585</idno><idno type="pmid">28447585</idno><idno type="doi">10.3851/IMP3171</idno><idno type="wicri:Area/PubMed/Corpus">000D50</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D50</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial.</title><author><name sortKey="Yao, Amanda H" sort="Yao, Amanda H" uniqKey="Yao A" first="Amanda H" last="Yao">Amanda H. Yao</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Moore, Cecilia L" sort="Moore, Cecilia L" uniqKey="Moore C" first="Cecilia L" last="Moore">Cecilia L. Moore</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Lim, Poh Lian" sort="Lim, Poh Lian" uniqKey="Lim P" first="Poh Lian" last="Lim">Poh Lian Lim</name><affiliation><nlm:affiliation>Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore.</nlm:affiliation></affiliation></author><author><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name><affiliation><nlm:affiliation>Department of Infectious Diseases, Hôpital Saint-Louis, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Madero, Juan Sierra" sort="Madero, Juan Sierra" uniqKey="Madero J" first="Juan Sierra" last="Madero">Juan Sierra Madero</name><affiliation><nlm:affiliation>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.</nlm:affiliation></affiliation></author><author><name sortKey="Kerr, Stephen" sort="Kerr, Stephen" uniqKey="Kerr S" first="Stephen" last="Kerr">Stephen Kerr</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Mallon, Paddy Wg" sort="Mallon, Paddy Wg" uniqKey="Mallon P" first="Paddy Wg" last="Mallon">Paddy Wg Mallon</name><affiliation><nlm:affiliation>School of Medicine, University College Dublin, Dublin, Ireland.</nlm:affiliation></affiliation></author><author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW, Sydney, Australia.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Antiviral therapy</title><idno type="eISSN">2040-2058</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To investigate metabolic changes associated with second-line antiretroviral therapy (ART) following virological failure of first-line ART.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">28447585</PMID><DateCreated><Year>2017</Year><Month>04</Month><Day>27</Day></DateCreated><DateRevised><Year>2017</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2040-2058</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2017</Year><Month>Apr</Month><Day>27</Day></PubDate></JournalIssue><Title>Antiviral therapy</Title><ISOAbbreviation>Antivir. Ther. (Lond.)</ISOAbbreviation></Journal><ArticleTitle>Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.3851/IMP3171</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To investigate metabolic changes associated with second-line antiretroviral therapy (ART) following virological failure of first-line ART.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">SECOND-LINE was an open-label randomized controlled trial. Participants were randomized 1:1 to receive ritonavir-boosted lopinavir (LPV/r) with 2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI-group) or raltegravir (RAL-group) Two hundred and ten participants had a dual energy X-ray absorptiometry (DXA)-scan at baseline, week 48 and 96. We categorized participants according to second-line ART backbone: 1. thymidine analogue (ta-NRTI)+lamivudine/emtricitabine (3[F]TC) [ta-NRTI group]; 2. tenofovir (TDF)+3[F]TC [TDF group]; 3. TDF+ta-NRTI+/-3[F]TC [TDF+ta-NRTI group]; 4. RAL. Changes in fasted total cholesterol, LDL-cholesterol, HDL-c, TC/HDL-cholesterol ratio, triglycerides and glucose from baseline to week 96 were examined. We explored the association between metabolic and DXA-assessed soft-tissue changes. Linear regression methods were used.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We analyzed 454 participants. Participants in RAL group had greater TC increases TC (adjusted mean difference (aMD)=0.65, 95%CI 0.33, 0.96), LDL-c (aMD=0.38, 95%CI 0.15, 0.61) and glucose (aMD = 0.47, 95%CI -0.01, 0.92) compared to TDF group, and had greater increases in TC (aMD=0.65, 95%CI 0.28, 1.03), HDL-c (aMD=0.12, 95%CI 0.02, 0.23) and LDL-c (aMD=0.41, 95%CI 0.13, 0.69;) compared to TDF+ta-NRTI group. TC/HDL ratio and triglycerides increased in all groups without significant differences between groups. A 1kg increase in trunk fat mass was associated with an increase in TC.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We observed metabolic changes of limited clinical significance in the relatively young population enrolled in this study. However, the metabolic changes observed may have greater clinical significance in older people living with HIV or those with other concomitant cardiovascular risks.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Amanda H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>The Kirby Institute, UNSW, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Cecilia L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>The Kirby Institute, UNSW, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Poh Lian</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hôpital Saint-Louis, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Paris Diderot, Sorbonne Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madero</LastName><ForeName>Juan Sierra</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerr</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Kirby Institute, UNSW, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HIV-NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallon</LastName><ForeName>Paddy Wg</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emery</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Kirby Institute, UNSW, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Queensland, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>The Kirby Institute, UNSW, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyd</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>The Kirby Institute, UNSW, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Adelaide, Lyell McEwin Hospital, Elizabeth Vale, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>SECOND-LINE study group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Antivir Ther</MedlineTA><NlmUniqueID>9815705</NlmUniqueID><ISSNLinking>1359-6535</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>04</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28447585</ArticleId><ArticleId IdType="doi">10.3851/IMP3171</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D50 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000D50 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28447585
|texte= Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28447585" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |